Literature DB >> 19190145

Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival.

Ying-Chun Shen1, Fu-Chang Hu, Yung-Ming Jeng, Yu-Ting Chang, Zhong-Zhe Lin, Ming-Chu Chang, Chiun Hsu, Ann-Lii Cheng.   

Abstract

Mitosis dysregulation is common in cancers. This study explored the nuclear expression patterns and prognostic significance of mitotic regulatory proteins, including Aurora kinases, survivin, and p53, in biliary tract cancer (BTC). Archival tumor samples from 161 BTC patients who underwent surgery were tested for the expression of Aurora-A, Aurora-B, survivin, and p53 by immunohistochemistry. The potential endogeneity among the clinicopathologic variables and survival outcome was assessed by a generalized simultaneous equations model. Nuclear overexpression of Aurora-A, Aurora-B, survivin, and p53 was found in 79 (49.1%), 45 (28.0%), 55 (34.2%), and 55 (34.2%) patients, respectively. Intrahepatic cholangiocarcinoma, compared with the other two subtypes, had significantly higher proportions of nuclear overexpression of Aurora-B and survivin (37.8% and 47.3%, respectively). Simultaneous overexpression of Aurora-A and Aurora-B was correlated with that of p53. Overexpression of Aurora-B was also correlated with that of survivin and tumor grade. Our data indicate that simultaneous overexpression of Aurora-A and Aurora-B, suggesting dysregulated mitosis is associated with worse survival in patients with BTC. Independent prognostic factors for poor overall survival included simultaneous overexpression of Aurora-A and Aurora-B (hazard ratio, 1.997; 95% confidence interval, 1.239-3.219; P = 0.0045) and tumor grade (hazard ratio, 2.117; 95% confidence interval, 1.339-3.348; P = 0.0013) assessed by a multivariate analysis stratified by American Joint Committee on Cancer stage and p53 overexpression. Endogeneity testing suggested that nuclear overexpression of p53 and tumor type may influence patient survival through their interactions with Aurora-A/Aurora-B expression and tumor grade.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190145     DOI: 10.1158/1055-9965.EPI-08-0691

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Aurora kinase B activity is modulated by thyroid hormone during transcriptional activation of pituitary genes.

Authors:  Manuel Tardáguila; Elena González-Gugel; Aurora Sánchez-Pacheco
Journal:  Mol Endocrinol       Date:  2011-01-14

2.  Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma.

Authors:  P O Zhao; Xiaoying Li; Yali Lu; Lin Liu
Journal:  Oncol Lett       Date:  2015-06-03       Impact factor: 2.967

3.  High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.

Authors:  Pramila Ramani; Emile Sowa-Avugrah; Margaret T May
Journal:  Virchows Arch       Date:  2015-07-22       Impact factor: 4.064

4.  Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.

Authors:  Hye Sung Won; Myung Ah Lee; Eun-Seon Chung; Dong-Goo Kim; Young Kyoung You; Tae Ho Hong; In-Seok Lee
Journal:  BMC Cancer       Date:  2010-10-19       Impact factor: 4.430

5.  Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.

Authors:  Zhong-Zhe Lin; Yung-Ming Jeng; Fu-Chang Hu; Hung-Wei Pan; Hsin-Wei Tsao; Po-Lin Lai; Po-Huang Lee; Ann-Lii Cheng; Hey-Chi Hsu
Journal:  BMC Cancer       Date:  2010-08-28       Impact factor: 4.430

6.  Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls.

Authors:  Min Wu; Chen Mao; Qing Chen; Xin-Wei Cu; Wei-Seng Zhang
Journal:  Mol Biol Rep       Date:  2009-08-20       Impact factor: 2.316

7.  Comprehensive analysis of DNA methylation and gene expression profiles in cholangiocarcinoma.

Authors:  Cheng Zhang; Bingye Zhang; Di Meng; Chunlin Ge
Journal:  Cancer Cell Int       Date:  2019-12-26       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.